Narcolepsy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Narcolepsy stocks.

Narcolepsy Stocks Recent News

Date Stock Title
Nov 1 TEVA Teva long-acting olanzapine shows improvements in schizophrenia patients
Nov 1 TEVA Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Nov 1 TEVA Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well ...
Nov 1 AVDL US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle
Nov 1 HRMY Earnings Beat: Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 1 TEVA Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Nov 1 AVDL Loss-Making Avadel Pharmaceuticals plc (NASDAQ:AVDL) Expected To Breakeven In The Medium-Term
Nov 1 TEVA EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
Oct 31 JAZZ Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
Oct 31 TEVA Teva fined $500M by EU for disparaging rival MS drug (update)
Oct 31 JAZZ Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Oct 31 TEVA EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
Oct 31 HRMY Harmony Biosciences Holdings Third Quarter 2024 Earnings: Beats Expectations
Oct 31 TEVA Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns
Oct 31 AVDL Avadel soars after court rules in favor of FDA in Lumryz case with Jazz Pharma
Oct 31 TEVA Teva Statement on European Commission Decision; Company to Appeal
Oct 31 ZVRA Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
Oct 31 AVDL Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
Oct 31 AVDL Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Oct 31 HRMY Harmony Biosciences prices secondary offering at $31 per share
Narcolepsy

Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that usually last from seconds to minutes and may occur at any time. About 70% of those affected also experience episodes of sudden loss of muscle strength, known as cataplexy. These experiences can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations while falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.The exact cause of narcolepsy is unknown, with potentially several causes. In up to 10% of cases, there is a family history of the disorder. Often, those affected have low levels of the neuropeptide orexin, which may be due to an autoimmune disorder. Trauma, infections, toxins or psychological stress may also play a role. Diagnosis is typically based on the symptoms and sleep studies, after ruling out other potential causes. Excessive daytime sleepiness can also be caused by other sleep disorders such as sleep apnea, major depressive disorder, anemia, heart failure, drinking alcohol and not getting enough sleep. Cataplexy may be mistaken for seizures.While there is no cure, a number of lifestyle changes and medications may help. Lifestyle changes include taking regular short naps and sleep hygiene. Medications used include modafinil, sodium oxybate and methylphenidate. While initially effective, tolerance to the benefits may develop over time. Tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) may improve cataplexy.About 0.2 to 600 per 100,000 people are affected. The condition often begins in childhood. Men and women are affected equally. Untreated narcolepsy increases the risk of motor vehicle collisions and falls. The term "narcolepsy" is from the French narcolepsie. The French term was first used in 1880 by Jean-Baptiste-Édouard Gélineau, who used the Greek νάρκη (narkē), meaning "numbness", and λῆψις (lepsis) meaning "attack".

Browse All Tags